
Oncology
Sacituzumab Tirumotecan Improves PFS in Advanced NSCLC
Interim phase 3 results favor adding sacituzumab tirumotecan to first-line pembrolizumab for PD-L1-positive advanced NSCLC, but survival, safety and generalizability remain unsettled.
Rayan Salih · September 16, 2026 · 6 min
